FYFan‐Wei Yang

Fan‐Wei Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fan‐Wei Yang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Network-based exploration of 4-(phenylsulfonyl)morpholine molecules for metastatic triple-negative breast cancer suppression

    by Jung-Chen Su, Chen-Ling Lee, Fan-Wei Yang, Yan-Chih Chen, Te-Lun Mai

    Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer, with limited treatment options due to the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) expression. This characteristic renders TNBC resistant to hormone-based and HER2-targeted therapies, leaving cytotoxic chemotherapy as the predominant strategy and highlighting the urgency for novel interventions. In this study, we investigated the mechanism of action of GL24, a potent 4-(phenylsulfonyl)morpholine-based small molecule with selective tumor suppression effects on metastatic TNBC cells, while being ineffective against TNBC cells derived from the primary tumor site, using gene co-expression analysis. By considering the distinct phenotypic responses induced by GL24, we tailored our co-expression analysis approach, selecting gene pairs that exhibited differential co-expression in effective cells while excluding gene pairs that also showed differential patterns in non-effective cells. Constructing a co-expression network from these differential pairs, followed by enrichment analysis and functional annotation, revealed specific gene interactions and molecular pathways associated with GL24-mediated TNBC inhibition. These insights supported the previously established findings that showed convergence on apoptosis based on differentially expressed genes, while also providing complementary information by highlighting pathways involved in metabolic alterations, proliferation, and migration or invasion. This expanded understanding advances the knowledge of the mechanisms of GL24 in combating TNBC.

  • Systematic synthesis and identification of monolignol pathway metabolites

    by Chung‐Ting Kao, Fan‐Wei Yang, Meng‐Chen Wu, Tzu‐Huan Hung, Chen‐Wei Hu, Chiu‐Hua Chen, Pin‐Chien Liou, Te‐Lun Mai, Chia‐Chih Chang, Tung‐Yi Lin, et al.

    Summary: Monolignol serves as the building blocks to constitute lignin, the second abundant polymer on Earth. Despite two decades of diligent efforts, complete identification of all metabolites in the currently proposed monolignol biosynthesis pathway has proven elusive. This limitation also hampers their potential application. One of the primary obstacles is the challenge of assembling a collection of all molecules, because many are commercially unavailable or prohibitively costly. In this study, we established systematic pipelines to synthesize all 24 molecules through the conversions between functional groups on a core structure followed by the application to other core structures. We successfully identified all of them in Populus trichocarpa and Eucalyptus grandis, two representative species respectively from malpighiales and myrtales in angiosperms. Knowledge about monolignol metabolite chemosynthesis and identification will form the foundation for future studies.


  • Open Access

    Discovery of N,N'‐diarylurea molecules with activity against multidrug‐resistant Staphylococcus aureus

    by Hui‐Hui Yeo, Yu‐Hsuan Jao, Fan‐Wei Yang, Min‐Hsuan Kuo, Meng‐Hsuan Lee, Chung‐Wei Shiau, Hao‐Chieh Chiu, Jung‐Chen Su

    The emergence and global spread of methicillin‐resistant Staphylococcus aureus (MRSA) pose a serious threat to public health, underscoring the urgent need for novel antibacterial interventions. Here, we screened 18 newly synthesized N,N’‐diarylurea derivatives to identify compounds with activity against MRSA. Our investigations led to the discovery of a small molecule, SCB‐24, which exhibited promising antimicrobial activity against MRSA USA300. Notably, SCB‐24 demonstrated high activity even in the presence of 10% fetal bovine serum and showed excellent selectivity for bacterial over mammalian cells. SCB‐24 also showed potent activity against various MRSA strains, including those resistant to second‐ and third‐line antibiotics. Importantly, the efficacy of SCB‐24 was inferior to that of vancomycin in MRSA‐infected Galleria mellonella larvae. Overall, our findings suggest that SCB‐24 has great potential as a new therapeutic for multidrug‐resistant S. aureus infections.


  • Open Access

    Multipathway regulation induced by 4‐(phenylsulfonyl)morpholine derivatives against triple‐negative breast cancer

    by Fan‐Wei Yang, Te‐Lun Mai, Ying‐Chung Jimmy Lin, Yu‐Chen Chen, Shang‐Che Kuo, Chia‐Ming Lin, Meng‐Hsuan Lee, Jung‐Chen Su

    Phenotypic drug discovery (PDD) is an effective drug discovery approach by observation of therapeutic effects on disease phenotypes, especially in complex disease systems. Triple‐negative breast cancer (TNBC) is composed of several complex disease features, including high tumor heterogeneity, high invasive and metastatic potential, and a lack of effective therapeutic targets. Therefore, identifying effective and novel agents through PDD is a current trend in TNBC drug development. In this study, 23 novel small molecules were synthesized using 4‐(phenylsulfonyl)morpholine as a pharmacophore. Among these derivatives, GL24 (4m) exhibited the lowest half‐maximal inhibitory concentration value (0.90 µM) in MDA‐MB‐231 cells. To investigate the tumor‐suppressive mechanisms of GL24, transcriptomic analyses were used to detect the perturbation for gene expression upon GL24 treatment. Followed by gene ontology (GO) analysis, gene set enrichment analysis (GSEA), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, multiple ER stress‐dependent tumor suppressive signals were identified, such as unfolded protein response (UPR), p53 pathway, G2/M checkpoint, and E2F targets. Most of the identified pathways triggered by GL24 eventually led to cell‐cycle arrest and then to apoptosis. In summary, we developed a novel 4‐(phenylsulfonyl)morpholine derivative GL24 with a strong potential for inhibiting TNBC cell growth through ER stress‐dependent tumor suppressive signals.